National Cancer Center
National Cancer Center
Goyang-si, Gyeonggi-do, South Korea32 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder | Recruiting | Phase 3 | 2026-10-08 | NCT07549412 | |
| Robotic Bronchoscopy for Small Lung Nodules Without a Bronchus Sign | Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Thoracic Neoplasms, disease, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm | Not yet recruiting | Not stated | 2026-10-07 | NCT07862816 | |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Intermediate Risk Non-Muscle Invasive Bladder Cancer | Recruiting | Phase 3 | 2026-10-07 | NCT06510374 | |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasm, Residual, Neoplasms by Histologic Type, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, large B-cell lymphoma, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 2 | 2026-10-02 | NCT06500273 | |
| A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer | HER2 positive breast carcinoma, Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-09-29 | NCT05132582 | |
| Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC | mCRPC | Active, not recruiting | Phase 3 | 2026-09-29 | NCT03395197 | |
| Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies | Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, carcinoma, epithelial neoplasm, head and neck cancer, head and neck squamous cell carcinoma, neoplasm, skin disorder, squamous cell carcinoma | Active, not recruiting | Phase 2 | 2026-09-09 | NCT05226871 | |
| Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2026-09-04 | NCT04821622 | |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, small cell lung carcinoma | Recruiting | Phase 3 | 2026-09-01 | NCT06712355 | |
| A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of Zanubrutinib | B-cell Malignancies | Active, not recruiting | Phase 3 | 2026-08-28 | NCT04170283 | |
| A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer | HER2-positive Breast Cancer | Active, not recruiting | Phase 3 | 2026-07-23 | NCT03975647 | |
| Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, transitional cell carcinoma, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, urothelial carcinoma | Active, not recruiting | Phase 3 | 2026-07-22 | NCT05911295 | |
| Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL | B-cell neoplasm, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, diffuse large B-cell lymphoma, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-07-22 | NCT04404283 | |
| Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, in situ carcinoma, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-07-10 | NCT04452591 | |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Adnexal Diseases, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Head and Neck Neoplasms, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, benign urinary system neoplasm, bronchial neoplasm, bronchogenic carcinoma, carcinoma, cervix disorder, digestive system disorder, digestive system neoplasm, endocrine system disorder, epithelial neoplasm, esophageal adenocarcinoma, esophageal disorder, esophageal squamous cell carcinoma, female reproductive system disorder, female reproductive system neoplasm, gastric neoplasm, gastroesophageal junction adenocarcinoma, gonadal disorder, head and neck squamous cell carcinoma, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, respiratory system disorder, respiratory tract neoplasm, squamous cell carcinoma, squamous cell neoplasm, stomach disorder, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder, uterine disorder | Recruiting | Phase 1 | 2026-07-06 | NCT04389632 | |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-06-30 | NCT06162221 | |
| (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors | Digestive System Diseases, Digestive System Neoplasms, Neoplasm Metastasis, Neoplasms by Histologic Type, Neoplasms, Connective and Soft Tissue, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, connective tissue neoplasm, digestive system disorder, digestive system neoplasm, gastrointestinal stromal tumor, metastatic malignant neoplasm, neoplasm | Recruiting | Phase 3 | 2026-06-16 | NCT05208047 | |
| A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer | Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colonic neoplasm, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorder, rectal neoplasm | Active, not recruiting | Phase 3 | 2026-06-11 | NCT04607421 | |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Adnexal Diseases, Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, biliary tract disorder, bronchial neoplasm, bronchogenic carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, endocrine system disorder, endometrium neoplasm, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, intestinal disorder, lung disorder, lung neoplasm, malignant endocrine neoplasm, neoplasm, non-small cell lung carcinoma, ovarian cancer, ovarian disorder, pancreas disorder, pancreatic neoplasm, rectal disorder, respiratory system disorder, respiratory tract neoplasm, uterine disorder | Active, not recruiting | Phase 1 / Phase 2 | 2026-05-29 | NCT04956640 | |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-05-27 | NCT05384626 | |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Site, Thoracic Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, lung disorder, lung neoplasm, neoplasm, respiratory system disorder, respiratory tract neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 1 | 2026-04-09 | NCT04794699 | |
| Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy | Disease Attributes, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 / Phase 3 | 2026-04-01 | NCT03315364 | |
| Phase II Trial of Pembrolizumab Plus Lenvatinib in Advanced Adrenal Cortical Carcinoma | Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, adrenal cortex disorder, adrenal cortex neoplasm, adrenal gland cancer, adrenal gland disorder, carcinoma, endocrine system disorder, epithelial neoplasm, malignant endocrine neoplasm, neoplasm | Active, not recruiting | Phase 2 | 2026-01-23 | NCT05036434 | |
| A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Male Urogenital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Non-Muscle Invasive Bladder Neoplasms, Urogenital Diseases, Urogenital Neoplasms, benign urinary system neoplasm, carcinoma, epithelial neoplasm, neoplasm, urinary bladder disorder, urinary bladder neoplasm, urinary system disorder | Active, not recruiting | Phase 3 | 2026-01-22 | NCT04165317 | |
| A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2025-10-21 | NCT04194944 |